Entospletinib
Entospletinib
Entospletinib (pronounced en-toh-spleh-tin-ib) is a selective inhibitor of the enzyme spleen tyrosine kinase (Syk). It is an experimental drug that is being studied for its potential use in the treatment of various types of cancer, including leukemia and lymphoma.
Etymology
The name "Entospletinib" is derived from the Greek word "entos", meaning "within", and "spleen", referring to the spleen tyrosine kinase that the drug targets. The "-ib" suffix is common in names of tyrosine kinase inhibitors.
Mechanism of Action
Entospletinib works by selectively inhibiting the activity of spleen tyrosine kinase, an enzyme that plays a crucial role in the signaling pathways of B cells and myeloid cells. By blocking this enzyme, Entospletinib can disrupt the growth and survival of cancer cells.
Clinical Trials
Entospletinib has been tested in several clinical trials for its potential use in treating various types of cancer. However, as of now, it has not been approved by the Food and Drug Administration (FDA) or any other regulatory authority.
Related Terms
- Spleen tyrosine kinase
- Tyrosine kinase inhibitors
- B cells
- Myeloid cells
- Clinical trials
- Food and Drug Administration
External links
- Medical encyclopedia article on Entospletinib
- Wikipedia's article - Entospletinib
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski